homopolymers (e.g. poly-lysine, poly-ornithine and poly-histidine) (6). In the same study it was shown that the ability of polyarginines to penetrate cells increased in proportion to the number of arginines. High cell uptake was observed with chain lengths of eight to fifteen arginine residues. However, chain lengths longer than fifteen arginine residues were much less successful in penetrating cells. Interestingly, homopeptides consisting of seven to nine arginines have been reported to display higher cellular uptake compared to the Tat peptide itself (7).
Transition metal complexes are being actively explored as novel chemotherapeutic agents (8) (9) (10) (11) . Their facile uptake into cells is important in order to achieve their therapeutic effect. Several studies exploring cell uptake of metal peptide conjugates have been reported. For example, Barton et al. have reported rhodium and 4 ruthenium-octa-arginine conjugates that are efficiently taken up by the cell and do not alter the site-specificity of the complexes (12) . An interesting method for the delivery of therapeutics to the cell nucleus has been described by Metzler-Nolte et al. (13) . Recently we and others have reported organometallic osmium(II) arene complexes with promising cancer cell cytotoxicity (14) (15) (16) (17) (18) (19) (20) (21) . Some of these complexes have been shown to induce non-repairable damage to DNA by causing a large degree of DNA unwinding (22) . In this work, we have attached polyarginines with varying chain lengths to osmium arene complexes and studied their in vitro toxicity, cellular uptake, cell distribution, DNA and albumin protein binding. We have investigated the effect of peptide chain length on cell and nucleus penetration, and effect on the cytotoxicity. This appears to be the first study to show that conjugation of biomolecules such as CPPs to these types of organometallic arene complexes can greatly influence their biological properties.
MATERIALS AND METHODS

Materials.
Parent complex 1, ([(η 6 -bip)Os(picolinate)Cl]), and precursor complex 2, ([(η 6 -bip)Os(4-CO 2 -picolinate)Cl]), were synthesized and characterized as previously described (19) . Solid-phase bound and protected arginine derivatives were purchased from Fluka, reaction syringes (5 mL) were bought from Multisyntech (Witten, Germany). TBTU (99.5% purity) and pipiridine (99% purity) from SigmaAldrich. The peptides Arg 5 and Arg 8 were purchased from Clonestar Peptide Services (Brno, Czech Republic). Recombinant human albumin (rHA) (batch A-1887, Lot 14H9319), supplied by Sigma, was dialyzed against 100 mM NH 4 HCO 3 , pH 7.9, and stored as a solution at 277 K. Calf thymus (CT) DNA (42 % G + C, mean molecular mass ca. 2 x 10 7 ) was prepared and characterized as described previously (23) (24) .
Tissue culture reagents were obtained from Invitrogen (Paisley, UK). The A2780 ovarian cancer cell line was obtained from the ECACC (European collection of cell culture, Salisbury, UK). The cells were maintained in RPMI 1640 and were supplemented with 10% foetal calf serum, 1% L-glutamine and 1%
penicillin/streptomycin. All cells were grown at 310 K in a humidified atmosphere containing 5% CO 2 .
Synthesis of peptide-conjugates compounds 3-6. The syntheses of compounds 3-6 were performed manually in a syringe equipped with a porous filter using ICP-MS analysis. The whole cell pellets, DNA samples and cytosol/nucleus fractionation samples were digested as described below. To the cell pellet was added 0.8 mL and to the extracts 0.4 mL of freshly-distilled 72% HNO 3 and the samples were then transferred into wheaton v-vials ® (Aldrich). The vials were heated in an oven at 373 K for 16 h. The vials were allowed to cool and then each sample was transferred to a volumetric tube. The vials were washed with doubly-deionised water (DDW) and diluted 10 times with DDW to obtain 7.2% HNO 3 sample solutions. Metalation reactions in a cell-free medium. CT DNA was incubated with Os II complex in 10 mM NaClO 4 (at pH 6) at 37°C in the dark. The amount of the metal complex was determined by flameless atomic absorption spectrometry (FAAS).
ICP-MS
Absorption spectra were measured with a Beckman DU 7 4000 spectrophotometer equipped with a thermoelectrically controlled cell holder and quartz cells with the pathlength of 1 cm. The FAAS measurements were carried out on a Varian AA240Z
Zeeman atomic absorption spectrometer equipped with a GTA 120 graphite tube atomizer.
RESULTS
Synthesis and characterization of peptide conjugates. Unfunctionalized
biphenyl Os II picolinate complex 1 and conjugation precursor p-carboxy picolinate complex 2 were synthesized as previously reported (15) (16) (17) (18) (19) . Complexes 3 and 4 containing a single lysine and arginine, respectively, and complexes 5 and 6, conjugates with five and eight arginines (Figure 1 ), respectively, were synthesized using solid phase methods (SPPS) as illustrated in Figure 2 . The Fmoc protected amino acids were activated and coupled to the resin with a TBTU/DIPEA mixture. In the final step, complex 2 was coupled to the resin with the same reaction mixture.
Cleavage from the resin was performed with standard Fmoc cleavage conditions (95% TFA), since osmium complex 2 was found to be stable under these strongly acidic conditions. The final products were purified using reverse-phase semi-preparative HPLC.
Two peaks assignable to the aqua adduct and the parent chlorido compound were observed in the RP-HPLC chromatogram (substitution of Cl by H 2 O). In addition, in all chromatograms of conjugates 3-6, a small amount of compound 2 was observed in both its aqua and chloride parent forms (see Figure S1 for an example of a RP-HPLC trace for 6). To ensure that the correct fractions had been isolated, the separated peaks were analysed using Micro-TOF mass spectrometry. Peaks belonging to several positively-charged species of the conjugates were observed in the mass spectra of all conjugates (see Figure 3 for 6), due to the ease of protonation of the arginine under neutral aqueous conditions.
Cytotoxicity.
We have previously found that osmium complex 1 exhibits promising activity in the A2780 human ovarian cancer cell line (IC 50 = 4.5 µ M) (15).
First we investigated whether the peptide conjugates would retain this activity.
Moderate cytotoxicity was observed for complexes 5 and 6 when tested in fetal-calfserum (FCS)-free conditions during the 24 h drug exposure time. The cytotoxicity increases with increase in length of the Arg chain, with an IC 50 value of 71.5 µM ± 2.5 for Arg 5 compound 5, and 32.9 µM ± 3 for Arg 8 compound 6. The dose-response curves for 5 and 6 are shown in Figure 4 . For control purposes, the IC 50 of cisplatin was also determined using the same assay (0.69 µM ± 0.15, Figure S2 ). Cellular uptake. The cellular uptake of complexes 1, 4-6 in the ovarian A2780 cancer cell line was compared to determine if the CPP-osmium conjugates show increased cellular uptake compared to unconjugated osmium complex 1.
Osmium uptake in A2780 cells was determined by ICP-MS after a 24 h exposure to the compounds in FCS-free medium. The highest intracellular levels of osmium were observed after exposure to the octarginine complex 6 (329.3±37.7 pmol Os/10 6 cells)
followed by the pentaarginine compound 5 (73.4±4.7 pmol Os/10 6 cells), with the lowest osmium concentrations being found for the monoarginine complex 4 and parent complex 1 (37.8±4.2 pmol Os/10 6 and 37.2±4 pmol Os/10 6 cells, respectively, in FCS-free medium was determined, and the results are shown in Figure 6 . For complexes 4-6, the sum of these fractions accounted for only about 40% of the whole cellular Os uptake, while for complex 1, 80% of the whole cell uptake was accounted for.
The cell distribution for unfunctionalized osmium complex 1 is very similar to that of monoarginine complex 4. The amount of osmium localizing in the cell nucleus increases with increasing arginine chain length (6 > 5 > 4 > 1, Figure 6A ). This amounts to 11% (1), 22% (4), 32% (5) and 44% (6) of the total amount of osmium in the fractions localizing in the cell nucleus, and 89% (1), 78% (4), 68% (5) and 56% (6) of osmium localizing in the cytosolic fractions ( Figure 6B ).
To investigate whether DNA is also a potential target for the osmiumbioconjugates, DNA was isolated from A2780 cells treated with complexes 4-6 and the levels of osmium on DNA were determined by ICP-MS (Figure 7) . The osmium content of DNA followed the order 6 > 5 > 4 (3.86±0.56 pmol Os/10 6 for 6, 0.87±0.27
pmol Os/10 6 cells for 5 and 0.26±0.08 pmol Os/10 6 cells for 4).
Binding to Albumin. The protein albumin constitutes about 60% of serum.
To investigate whether binding of the peptide conjugates to albumin was responsible for the inactivity of 3-6 when tested in FCS containing medium, complex 5 was 
DISCUSSION
The aim of the study was to investigate the possibility of conjugating cell penetrating peptides (CPPs) to organometallic osmium(II) anticancer complexes and determine whether this would lead to increased cell and nuclear uptake into ovarian A2780 cancer cells. Also the ability of the conjugates to bind to DNA was assessed as this is the proposed target for the parent complex 1. It should be noted that the parent picolinate complex itself (1) is taken up by cells without the attachment of a CPP (27) .
The attachment of a CPP may, however, no t only increase cellular uptake but also Cleavage from the resin and deprotection of the pbf side-chain protecting groups of arginine was achieved in strong acidic conditions of 95% TFA (see Figure 2 for the general synthetic procedure). The carboxylate derivative 2 was found to be very stable in such strong acidic conditions. This in combination with the good solubility of 2 in DMF and the strategically placed carboxylic acid functionality, made compound 2 a good candidate for peptide conjugation using SPPS.
The conjugates were purified using reverse-phase semi-preparative HPLC, and for all four compounds peaks assignable to the aqua adduct were visible in the chromatogram during separation indicating that hydrolysis of the osmium-chloride bond occurs rapidly ( Figure S1 ). The side-chains of arginine and lysine amino acids are strongly basic and are therefore readily protonated and observed in neutral aqueous conditions by mass spectrometry (Figure 3 ). These multiple charges confer good aqueous solubility on the conjugates.
Cancer Cell Cytoxicity. Complexes 3-6 were inactive at concentrations of up to 150 µ M when tested in media containing 10% foetal calf serum (FCS). Albumin is the most abundant serum protein (~60%), and it seemed likely that the peptide conjugates were binding strongly to albumin resulting in the loss of activity. There are several reported cases where the ability of certain CPPs to penetrate cells in vitro was enhanced in the absence of serum in the media (7, [28] [29] .
To test this hypothesis, the cells were treated with compounds for 24 h in a medium which was free of FCS. Cytotoxic activity was found for the pentaarginine conjugate 5 (IC 50 71.5 ± 2.5 µM), and increasing the chain length from five to eight arginines (complex 6) resulted in a more than two-fold increase in cytotoxicity (IC 50 32.9 ± 3.0 µM , is not a suitable strategy for improving the biological properties for these complexes.
Cell Distribution and DNA Uptake. The distribution of the peptide conjugates in isolated cell fractions (e.g. cytosol and nucleus) was determined for compounds 1, 46 after a 24 h exposure time. The amount of osmium detected in the nuclear fraction dramatically increased with increasing conjugation: 1 < 4 < 5 < 6 (e.g.
11% for 1, 23% for 4, 32% for 5 and 44% for 6, Figure 6) showing that increasing the arginine chain length not only increases cellular uptake but also increases cellular internalisation. Interestingly, almost half of the total amount of osmium from complex 6 was detected in the cell nucleus. This increase in uptake into the nucleus with the longer arginine chain length probably explains the higher cytotoxicity of 5 and 6.
Polyarginines and TAT-mediated delivery have been shown to increase cell internalisation with other cargos as well (33).
Nuclear DNA is a potential target for Os II arene compounds (22) . The target may be defined as a site within the cell which is altered by the drug and whose modification leads to cell death. Several criteria are used to suggest that a certain type of lesion is the critical lesion which kills the tumor cells. One of the criteria used to suggest that DNA is the target is based on the observation that a drug exhibits a higher toxicity in cells which are deficient in DNA repair (34). This is the case because the persistence of DNA lesions depends on the capacity of ce lls to repair the damage. The assay used in this work is based on introducing a point mutation in a gene coding one of the proteins necessary for the repair of DNA. Mutant Chinese hamster ovary CHO-K1 cells, MMC-2 carrying the ERCC3/XPB mutation, which are deficient in DNA repair, were significantly more sensitive to killing by complex 5 Os-Arg 5 and complex 6 Os-Arg 8 than were the wild type cells (Table 1) 
CONCLUSIONS
In this work we report the synthesis of osmium arene peptide conjugates by solid phase peptide synthesis (SPPS). The osmium arene parent complex (2) is very stable under aqueous and acidic conditions making it an ideal candidate for SPPS.
There is a correlation between longer arginine chain lengths and the cell uptake, nuclear uptake, DNA binding and cytotoxicity of the conjugates following the order 6 (eight arginine residues) >> 5 (five arginine residues) > 4 (one arginine) ~ 1 (unfunctionalized). In particular, osmium arene complexes 5 and 6 showed cytotoxicity in the ovarian cancer cell line that increased 2-fold going from five arginine residues (5) to eight arginine residues (6). Furthermore, osmium octaarginine conjugate (6) shows a 10-fold increase in cellular uptake and an over 15-fold increase in DNA binding compared to monoarginine compound 4. The high nuclear uptake for 6 is likely related to the observed high DNA binding and higher cytotoxicity for this compound compared to the other conjugates. It is likely that DNA is also the target 20 for the conjugates as experiments on CHO cells deficient in DNA repair suggested that unrepaired DNA damage contributes to the cytotoxicity of Os-Arg5 (5) and OsArg8 (6) complexes. The conjugates are less cytotoxic compared to the parent compound. This is likely due to the cationic nature of the peptide which can bind to other cellular components, as well as differences in binding to DNA. Indeed, the rates of DNA binding of the conjugates were 5-to 8-fold faster compared to the parent compound, and also the conjugates were able to precipitate DNA at very low concentrations, indicating a different interaction with DNA.
The large increase in cell uptake, nuclear localization and DNA binding of the osmium conjugate 6 compared to the parent (unfunctionalized) complex shows that attaching a CPP introduces desirable features into this type of complex. (Table   S1 ). RP-HPLC trace for the semipreparative purification of 6 ( Figure S1 ). Dose-response curve for cisplatin towards human ovarian A2780 cancer cells ( Figure S2 ).
This material is available free of charge via the Internet at http://pubs.acs.org.
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Tagging an anticancer organometallic arene Os II anticancer complex with 5 or 8 arginine residues greatly increases cellular, nuclear and DNA uptake in A2780 human ovarian cancer cells. The Arg 8 complex is cytotoxic and a rare example of a bioactive organometallic peptide conjugate, demonstrating the potential for use of cell-and nucleus-penetrating peptides in targeting organometallic arene anticancer complexes. 
